Royalty Report: Cancer, Drugs, Therapeutic – Collection: 7340

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Cancer
  • Drugs
  • Therapeutic
  • Delivery
  • Medical
  • Disease
  • Pharmaceuticals
  • Biotechnology
  • Device
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7340

License Grant
The Canadian Licensor entered into an exclusive License Agreement with the Japanese Licensee pursuant to which the Licensee was granted the right to develop and commercialize PRX302 in Japan for the treatment of the symptoms of BPH, prostate cancer, prostatitis or other diseases of the prostate.
License Property
The Licensor is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia, or BPH, commonly referred to as an enlarged prostate. PRX302 is designed to be a convenient treatment that is safer and less invasive than surgery and more effective and better tolerated than currently approved pharmaceutical therapies.

IPSCIO Record ID: 7324

License Grant
In this related party cross-license agreement the Company granted an exclusive license to use the Company’s technology for certain applications.

In return, the Licensee granted the Company an exclusive license to use Licensee's technology for certain applications.

License Property
TUNA® (transurethral needle ablation) system treats benign prostatic hyperplasia (BPH), a non-cancerous condition also known as “enlarged prostate.”

The TUNA System is designed to offer a minimally invasive alternative for the treatment of benign prostatic hyperplasia by selectively shrinking the hyperplastic tissue that compresses the urethra limiting urinary flow.

IPSCIO Record ID: 25837

License Grant
The Canadian Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, licensor's (Canadian) Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).
License Property
Under the terms of the agreement, licensee (Italian) receives exclusive rights to develop and subsequently market and sell NX-1207 in Europe including Russia and the CIS, the Middle East, the Maghreb area of North Africa and South Africa (i.e. a total of 81 countries).

NX-1207 is an office-based pro-apoptotic protein injectable for BPH and for low grade localized prostate cancer. The drug mechanism of action is to lead to programmed natural cell death (apoptosis) selectively in prostate glands when injected intraprostatically by the transrectal route.

Field of Use
The licensing agreement covers the use of NX-1207 for the treatment of BPH as the initial indication for development and commercialization.

IPSCIO Record ID: 1617

License Grant
The Company obtains an exclusive worldwide license to the Licensed Patents, probasin gene (PG) and to practice, use or sell the Licensed Processes from Canadian University.
License Property
Licensed Patents shall mean all patent applications respecting PG (a) International PCT Application Serial No. PCT CA 9300319 filed August 9, 1993 entitled DNA Sequences of Rat Probasin Gene; and (b) all patent applications respecting PG which may be filed from time to time by University pursuant to this Agreement.
Field of Use
Field of Use shall mean human gene therapy involving the transfer of genetic material into target mammalian cells in vitro or in vivo for the purpose of intercellular drug delivery and/or treatment of a disease or medical condition.

IPSCIO Record ID: 238982

License Grant
University hereby grants to Licensee an exclusive, worldwide right and license, with the right to grant Sublicenses and to permit Sub-sublicenses to practice under and use the Licensed Patents and the Licensed Technology to make, have made, use, market, sell, have sold, import, distribute, and offer for sale any Licensed Product, Licensed Process or Generic Product. University hereby agrees, subject to the terms and conditions herein contained, that the term 'exclusive' means that University shall not grant any other license to any third party or take any action inconsistent with the rights granted to Licensee under this Agreement relating to the Licensed Patents or Licensed Technology.
License Property
Licensed Patents shall mean
6,265,448 – Method for chemoprevention of prostate cancer
6,413,533 – Method for chemoprevention of prostate cancer
6,413,534 – Method for chemoprevention of prostate cancer
6,410,043 – Method for chemoprevention of prostate cancer
6,413,535 – Method for chemoprevention of prostate cancer

Licensed Technology shall mean any technology, trade secrets, methods, processes, know-how, show-how, data, information, or results relating to the patent applications, developed by the Contributors and owned by University, including the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent or pharmaceutical preparation comprising an anti-estrogen or SERM, including, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis.

Field of Use
Patents relate to toremifene for the reduction in the incidence of prostate cancer in men with high grade PIN and its composition of matter and method of use patents and patent applications relating to Andarine to market, distribute and sell licensed products.

IPSCIO Record ID: 328171

License Grant
For the option, Licensor grants to Licensee of the United Kingdom, upon exercise of the Option, throughout  the  territory, for the sole purpose of developing, making, having made, using and selling  BPH products, a non-exclusive license under the patents.

For the Licenses, Licensor grants throughout the territory, for the sole purpose of developing, making, having made, using and selling selective Alpha-1 an Adrenergic Receptor Products which are not BPH Products, a non-exclusive license under any of the Receptor patents. The section of the license grant shall extend back in time to apply to acts by Licensee prior to the Effective Date of this agreement.

Licensor grants, throughout the Territory, for the sole purpose of developing, making, having made and using but not selling BPH Products a nonexclusive license under the Receptor Patents.

Licensor grants, throughout the Territory, for the sole purpose of developing, making, having made and using but not selling BPH Products a nonexclusive license under the Functional Use Patents.

Upon exercise of the Option, Licensor grants throughout the Territory, for the sole purpose of developing, making, having made, using and selling BPH Products a non-exclusive license under the Patents.

License Property
Licensor possesses patent rights pertaining to the use of selective human alpha-1a adrenergic receptor compounds which may be useful for the  treatment of benign prostate hyperplasia (BPH) and other medical conditions and cloned human alpha-1a, -1b and -1d adrenergic receptors.

BPH Compound shall mean any Selective Alpha-1a  Adrenergic Receptor Compound for which regulatory approval to sell for the treatment of BPH or for the  inhibition of  contraction  of prostate  tissue has been obtained or is being sought.

BPH Product shall mean any prescription or over-the-counter pharmaceutical preparation containing BPH  Compounds for use in humans.

Human Alpha-1 Adrenergic Receptors shall mean alpha-1a , alpha-1b, and, alpha-1d.

Selective Alpha-1 Adrenergic Receptor Product shall mean any prescription or over-the-counter pharmaceutical preparation containing Selective Alpha-1a Adrenergic Receptor Compounds for use in human or non-human animals.

Field of Use
Alpha-1a adrenergic receptor compounds may be useful for the  treatment of benign prostate hyperplasia (BPH).

The Therapeutic indication shall mean,  with respect to any Selective Alpha-1a Adrenergic Receptor Product, the main therapeutic use as classified in the 2nd level of the World Health Organization Anatomical, Therapeutic, Clinical (ATC) drug classification system.

Licensee is developing  selective human alpha-1a  adrenergic receptor  compounds  which may be useful for the  treatment of BPH and other medical conditions and is using cloned human alpha-1 adrenergic receptors.

IPSCIO Record ID: 29294

License Grant
The Company granted the development partners exclusive licenses to use the Geomatrix technology in products throughout the world.
License Property
A significant part of the Company's business is developing applications of its Geomatrix(TM) technologies. Geomatrix is a range of technologies by which drugs taken orally in tablet form are formulated so as to control the amount, timing and location of the release of the drug in the body. The Company focuses its research and development efforts on the reformulation of existing drugs using its technologies rather than the discovery of new chemical compounds.
Field of Use
Xatral 10mg OD is a once per day Zero Order Geomatrix formulation of Alfuzosin used for the treatment of the functional symptoms of benign prostatic hyperplasia (BPH), a common disorder in men over the age of 50.

IPSCIO Record ID: 299258

License Grant
This agreement is to compromise, resolve and settle all asserted and unasserted claims relating to the allegations, and license technology.

Licensor grants an irrevocable, non-exclusive, worldwide right and license under the Licensed Patents only within the Technology Field to undertake Product Related Activities for Licensed Products and develop, make, have made, market, use, authorize others to use, import, distribute, sell, have sold and offer to sell Licensed Products, for the life of the Licensed Patents.

License Property
The patents are for Urethral inserted applicator for prostate hyperthermia and therapeutic prostatic thermotherapy.

Licensed Products shall mean Licensees Current Products and Reasonable Modifications thereof developed, manufactured, used, marketed, offered for sale, sold, imported, licensed or distributed by or on behalf of a Licensee Party or a permitted successor or assign under this Agreement, directly or through their respective manufacturers, distributors, contractors, resellers, and other intermediaries.

Current Products of a Party shall mean products and components thereof commercially available from that Party or its Affiliates at or before the Effective Date in the Technology Field, which for Licensee is the Prolieve Thermodilation System and for Licensor is the TherMatrx System.

Prolieve Thermodilation System offers a unique “Thermodilatation” treatment for symptoms of enlarged prostate, also known as benign prostatic hyperplasia (BPH). Prolieve® is a combination therapy simultaneously using Focused Microwave Heating together with Pressurized Balloon Dilatation therapy.

Field of Use
Licensee is, in part, in the business of developing, making, marketing and selling products, therapies and technologies that use heat generated by microwave energy to treat benign prostatic hyperplasia, including a product currently sold under the brand Prolieve Thermodilation System®.

Technology Field shall mean the field of microwave therapy for treating benign prostatic hyperplasia (BPH) and prostatitis.

IPSCIO Record ID: 203339

License Grant
The Licensor of Finland grants to Licensee an exclusive right and license, with the right to grant sublicenses under Licensor Patent Rights and Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the Field in the Licensee Territory, except in the Licensor Field in the Licensor Territory; and a non-exclusive right and license, with the right to grant sublicenses, under the Licensor Patents and Know-How, to perform research and preclinical development activities, using the Powder to be provided to Licensor, except in the Licensor Field in the Licensee Territory.
License Property
The Product shall mean any pharmaceutical product for human use within the Field containing Toremifene as a therapeutically active ingredient.

The Fareston Product shall mean the Orion Product in 60 mg tablet form containing Toremifene that was promoted in the USA under the brand name Fareston by Shire prior to the Restatement Date for use in the Breast Cancer Field.

Toremifene shall mean [tore mi f ene citrate and/or the Z-isomer of 4-chloro-1, 2 diphenyl-1-(4-(2-(N,N-dimethylamino)-ethoxy) – phenyl]- 1 -butene].

Field of Use
The field means all uses of a Product in humans, with a current use of treatment of prostate cancer. The Parties expressly acknowledge that the use of Product in the field of animal health is excluded from the scope of this Agreement.

IPSCIO Record ID: 203383

License Grant
The Licensor of Finland grants an exclusive right and license, with the right to grant sublicenses, under Licensor Patent Rights and Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the North American Territory and in Japan in the Field;
– a non-exclusive right and license, with the right to grant sublicenses, under Licensor Patent Rights and
Licensor Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the ROW Territory for exclusive use in the Field;
– a non-exclusive license, under the Licensor Patents and Know-How, to perform research and preclinical development activities using the Powder.
License Property
The product means any pharmaceutical product for human use within the Field containing Toremifene as a therapeutically active ingredient.

Toremifene' shall mean [toremifene citrate and/or 4-chloro-l, 2 diphenyl-1-(4(2-(N,N-dimethylamino)-ethoxyl) – phenyl] -I-butene].

Toremifene is a selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen which opposes the actions of estrogens like estradiol in the body and is approved for use in the treatment of advanced (metastatic) breast cancer.

Field of Use
The field means the prevention and treatment of prostate cancer, which shall mean for purposes hereof preventing prostate carcinogenesis; suppressing or inhibiting prostate cancer; reducing the risk of developing prostate cancer; increasing the survival rate of a subject with prostate cancer; and treating prostate cancer.

IPSCIO Record ID: 344493

License Grant
Licensor of Germany grants an exclusive license to use Licensors Patent Rights and Licensors Know-How to develop, use, make, have made, sell, offer for sale, have sold, import and export, commercialize Contract Products and/or D-63153 in the Field and in the Territory. The license shall include the right to use Licensors Patent Rights and Know-How in conducting research and development activities with respect to the use of Contract Products and/or D-63153 in the Field and in the Territory.

Licensor grants a right of first negotiation to Licensee in case Licensee intends to license from Licensor any additional analogs which all under a valid claim of the LHRH Patents in the United States.

License Property
Contract Products shall mean and include all pharmaceutical products manufactured by Licensee, whether as mono-preparations or combination preparations, with the D63153 as an active ingredient, for use in the Field.

The active ingredient is referred to as ozarelix.  Ozarelix is a Luteinizing Hormone Releasing Hormone, or LHRH, antagonist (a substance that blocks the effects of a natural hormone found in the body). Mechanistically, LHRH antagonists exert rapid inhibition of luteinizing hormone and follicle stimulating hormone with an accompanying rapid decrease in sex hormones and would therefore be expected to be effective in a variety of hormonally dependent disease states including ovarian cancer, prostate cancer, BPH, infertility, uterine myoma and endometriosis.

LHRH Patents shall mean the composition in matter patents regarding a novel LHRH antagonist having improved solubility properties· with the internal No. 98/20 PH, the LHRH.

The patents are titled
— LHRH antagonists having improved solubility properties,
— Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof,
— Application of initial Doses of LHRH Analogues and Maintenance Doses of LHRH Antagonists for the Treatment of Hormone-dependent Cancers and Corresponding Pharmaceutical Kits, and,
— Use of LHRH Antagonists for intermittent Treatments.

Field of Use
The Initial indication shall mean the use of D-63153 and/or Contract Products for prostate cancer and benign prostate hyperplasia (BPH).

IPSCIO Record ID: 28967

License Grant
The Canadian Licensor grants the Licensee, a Joint Venture, the right to perform all necessary clinical testing of the Products within the Territory, seek all Product Approvals of the Products from all Regulatory Authorities within the Territory, and to market and distribute the Products within each country or jurisdiction in the Territory during the Term.

The Licensor hereby grants the Licensee a license to use the Trademarks solely in connection with the testing, marketing, distribution, import, export, use, offer to sell and sale of the Products in the Territory during the Term of this Agreement.

License Property
Products mean the PROLIEVE System, any of its component products (including, without limitation, the Control Unit and the Catheter Kit); any BPH, benign prostatic hyperplasia, products developed  from the Intellectual Property, and all Improvements to any of the foregoing.

Catheter Kit means the single-use disposable components of the PROLIEVE System.

The Prolieve system provides a 45-minute in-office treatment that combines our microwave thermotherapy capability with a proprietary balloon compression technology to both heat the prostate and dilate the prostatic urethra. The purpose of the Prolieve system is to provide a relatively painless and effective alternative to drug therapy and certain types of surgical procedures to treat the symptoms of BPH.

Field of Use
The Licensee shall have an exclusive license, solely to perform clinical tests, obtain Product Approvals from all Regulatory Authorities, and to market, distribute, have distributed, import, export, use, sell, and offer to sell the Products, in the Territory.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.